Read the latest updates about the COVID-19 vaccine at Fox Chase →
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Associate Professor, Department of Radiation Oncology
Chief, Division of Head and Neck Radiation Oncology
Medical Director, Clinical Research
I joined Fox Chase after completing my residency at the University of Florida in 2010. I specialize in treating cancers of the head and neck and skin cancer.
Cancer is a complicated, confusing diagnosis. Cancers of the head and neck are particularly challenging because they occur in areas that can affect our ability to perform some of our most basic functions: breathing, speaking, and eating.
I came to Fox Chase because I believe that the best way to cure these difficult cancers while maintaining quality of life is through a multi-disciplinary approach. Some cancers are cured with radiation alone, some need the assistance of both surgery and chemotherapy, and some are cured without radiation. The team approach at Fox Chase ensures that many different disciplines are working together to decide the best treatment for your unique case with one unifying goal: curing your cancer while avoiding unnecessary toxicity
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. The Survival Impact of Increasing Time to Treatment Initiation for Patients with Head and Neck Cancer in the United States. Accepted for publication in Journal of Clinical Oncology PubMed
Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, Galloway TJ. Pre-Treatment Tumor-Specific Growth Rate as a Temporal Biomarker that Predicts Treatment Failure and Improves Risk Stratification for Oropharyngeal Cancer. Accepted for publication in Oral Oncology PubMed
Lango MN, Galloway TJ, Mehra R, Ebersole B, Liu JC, Burtness B, Moran K, Ridge JA. Impact of baseline dysphagia on acute feeding tube placement in head and neck cancer patients undergoing definitive radiation. Epub ahead of print in Head and Neck PubMed
Galloway TJ, Ridge JA. Management of squamous cancer metastatic to cervical nodes with unknown primary. Epub ahead of print in Journal of Clinical Oncology PubMed
Galloway TJ, Wirth L, Colevas D, Gilbert J, Bauman J, Saba N, Raben D, Mehra R, Burtness B, Jimeno A. A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma (Clinical Cancer Research 2015; 21(7) 1566-1573). PubMed
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. Increasing time to treatment initiation for squamous cell carcinoma of the head and neck: An analysis of the National Cancer Database. (Cancer 2015; 121(8) 1204-1213). PubMed
Nguyen-Tan PF, Zhang QE, Ang KK, Wheeler RH, Weber RS, Rosenthal DI, Bahary JP, Kim H, Silverman C, Raben A, Galloway T, Vigneault E, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. A Randomized Phase III Trial to Test Accelerated versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Long Term Report of Efficacy and Toxicity. (Journal of Clinical Oncology 2014; 32(34) 3858-3867
Lango MN, Egleston B, Fang CY, Burtness B, Galloway T, Liu JC, Mehra R, Ebersole B, Moran KM, Ridge JA. Baseline Health Perceptions, weight-loss and survival in head and neck cancer. (Cancer 2014; 120(6):840-7
Keller L, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango M, Burtness B, Mehra M, Ridge JA. p16 Status, Pathologic and Clinical Characteristics, Biomolecular Signature, and Long Term Outcomes in Unknown Primary Carcinomas of the Head and Neck. (Head and Neck 2014 36(12) 1677-1684
Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder D, Ridge JA, Galloway TJ. Dysplasia at the Margin? Investigating the case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue. (Oral Oncology 2013 49(11): 1083-1087)
Burtness B, Bauman J, Galloway T. Novel Targets in HPV-Negative Head and Neck Cancer – Overcoming Resistance to EGFR Inhibition. (Lancet Oncology 2013; 14(8): e302-9).
Lango M, Flieder D, Arrangoiz R, Yu M, Li T, Burtness B, Mehra R, Galloway T, Veloski C, Ridge JA. Effect of extranodal extension on biochemical endpoints, nodal persistence and systemic disease progression in metastatic papillary thyroid carcinoma. (Thyroid. 2013; 23(9): 1099-1105)
Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral Neck Therapy in the Human Papillomavirus Era: Accepted Regional Spread Patterns. (Head and Neck. 2013; 35(2): 160-164)
Galloway TJ, Amdur RJ, Liu C, Yeung A, Mendenhall WM. Revisiting Unnecessary Larynx Irradiation with Whole Neck IMRT. (Practical Radiation Oncology. 2011 1, 27-32)
Galloway TJ, Morris CG, Mancuso AA, Amdur RJ, Mendenhall WM. Impact of Radiographic Findings on Prognosis for Skin Cancer with Clinical Perineural Invasion. Cancer. 2005 Mar 15; 103(6):1254-7 PubMed
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Associate Professor, Department of Radiation Oncology
Chief, Division of Head and Neck Radiation Oncology
Medical Director, Clinical Research
I joined Fox Chase after completing my residency at the University of Florida in 2010. I specialize in treating cancers of the head and neck and skin cancer.
Cancer is a complicated, confusing diagnosis. Cancers of the head and neck are particularly challenging because they occur in areas that can affect our ability to perform some of our most basic functions: breathing, speaking, and eating.
I came to Fox Chase because I believe that the best way to cure these difficult cancers while maintaining quality of life is through a multi-disciplinary approach. Some cancers are cured with radiation alone, some need the assistance of both surgery and chemotherapy, and some are cured without radiation. The team approach at Fox Chase ensures that many different disciplines are working together to decide the best treatment for your unique case with one unifying goal: curing your cancer while avoiding unnecessary toxicity
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. The Survival Impact of Increasing Time to Treatment Initiation for Patients with Head and Neck Cancer in the United States. Accepted for publication in Journal of Clinical Oncology PubMed
Murphy CT, Devarajan K, Wang LS, Mehra R, Ridge JA, Fundakowski C, Galloway TJ. Pre-Treatment Tumor-Specific Growth Rate as a Temporal Biomarker that Predicts Treatment Failure and Improves Risk Stratification for Oropharyngeal Cancer. Accepted for publication in Oral Oncology PubMed
Lango MN, Galloway TJ, Mehra R, Ebersole B, Liu JC, Burtness B, Moran K, Ridge JA. Impact of baseline dysphagia on acute feeding tube placement in head and neck cancer patients undergoing definitive radiation. Epub ahead of print in Head and Neck PubMed
Galloway TJ, Ridge JA. Management of squamous cancer metastatic to cervical nodes with unknown primary. Epub ahead of print in Journal of Clinical Oncology PubMed
Galloway TJ, Wirth L, Colevas D, Gilbert J, Bauman J, Saba N, Raben D, Mehra R, Burtness B, Jimeno A. A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma (Clinical Cancer Research 2015; 21(7) 1566-1573). PubMed
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder D, Ridge JA. Increasing time to treatment initiation for squamous cell carcinoma of the head and neck: An analysis of the National Cancer Database. (Cancer 2015; 121(8) 1204-1213). PubMed
Nguyen-Tan PF, Zhang QE, Ang KK, Wheeler RH, Weber RS, Rosenthal DI, Bahary JP, Kim H, Silverman C, Raben A, Galloway T, Vigneault E, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. A Randomized Phase III Trial to Test Accelerated versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Long Term Report of Efficacy and Toxicity. (Journal of Clinical Oncology 2014; 32(34) 3858-3867
Lango MN, Egleston B, Fang CY, Burtness B, Galloway T, Liu JC, Mehra R, Ebersole B, Moran KM, Ridge JA. Baseline Health Perceptions, weight-loss and survival in head and neck cancer. (Cancer 2014; 120(6):840-7
Keller L, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango M, Burtness B, Mehra M, Ridge JA. p16 Status, Pathologic and Clinical Characteristics, Biomolecular Signature, and Long Term Outcomes in Unknown Primary Carcinomas of the Head and Neck. (Head and Neck 2014 36(12) 1677-1684
Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder D, Ridge JA, Galloway TJ. Dysplasia at the Margin? Investigating the case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue. (Oral Oncology 2013 49(11): 1083-1087)
Burtness B, Bauman J, Galloway T. Novel Targets in HPV-Negative Head and Neck Cancer – Overcoming Resistance to EGFR Inhibition. (Lancet Oncology 2013; 14(8): e302-9).
Lango M, Flieder D, Arrangoiz R, Yu M, Li T, Burtness B, Mehra R, Galloway T, Veloski C, Ridge JA. Effect of extranodal extension on biochemical endpoints, nodal persistence and systemic disease progression in metastatic papillary thyroid carcinoma. (Thyroid. 2013; 23(9): 1099-1105)
Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral Neck Therapy in the Human Papillomavirus Era: Accepted Regional Spread Patterns. (Head and Neck. 2013; 35(2): 160-164)
Galloway TJ, Amdur RJ, Liu C, Yeung A, Mendenhall WM. Revisiting Unnecessary Larynx Irradiation with Whole Neck IMRT. (Practical Radiation Oncology. 2011 1, 27-32)
Galloway TJ, Morris CG, Mancuso AA, Amdur RJ, Mendenhall WM. Impact of Radiographic Findings on Prognosis for Skin Cancer with Clinical Perineural Invasion. Cancer. 2005 Mar 15; 103(6):1254-7 PubMed
24 PATIENT COMMENTS